METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS

(19)

(11)

EP 1 441 724 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	17.10.2007 Bulletin 2007/42

(45)	Mention of the grant of the patent:
	05.09.2007 Bulletin 2007/36

(21)	Application number: 02766382.2

(22)	Date of filing: 27.09.2002

(51)

International Patent Classification (IPC):

A61K 31/415^(2006.01)
A61K 31/4709^(2006.01)
A61K 31/4545^(2006.01)
A61K 31/497^(2006.01)
A61P 15/08^(2006.01)

A61K 31/4439^(2006.01)
A61K 31/4725^(2006.01)
A61K 31/4155^(2006.01)
A61P 5/26^(2006.01)

(86)	International application number:
	PCT/US2002/030801

(87)	International publication number:
	WO 2003/026649 (03.04.2003 Gazette 2003/14)

(54)	METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS VERFAHREN ZUR ERHÖHUNG DES TESTOSTERONSPIEGELS METHODES POUVANT AUGMENTER DES CONCENTRATIONS EN TESTOSTERONE ENDOGENE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

27.09.2001 US 325470 P

(43)	Date of publication of application:
	04.08.2004 Bulletin 2004/32

(73)	Proprietor: Laboratoires Serono SA
	1267 Coinsins, Vaud (CH)

(72)	Inventors:
	BRONDYK, William, H. Mansfield, MA 02048 (US) MCKENNA, Sean Duxbury, MA 02332 (US) ARKINSTALL, Stephen, J. Belmont, MA 02478 (US)

(74)	Representative: Merck Serono International S.A. Intellectual Property
	Intellectual Property Department 9, chemin des Mines 1202 Geneva 1202 Geneva (CH)

(56)

References cited: :

WO-A-00/66612
WO-A-02/18346
WO-A-95/13069
WO-A-99/23091

WO-A-01/87287
WO-A-94/13661
WO-A-98/52941

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1983 SANTUCCI L ET AL: "INHIBITION OF TESTOSTERONE PRODUCTION BY RAT LEYDIG CELLS WITH ETHANOL AND ACETALDEHYDE PREVENTION OF ETHANOL TOXICITY WITH 4 METHYL PYRAZOLE" Database accession no. PREV198477023774 XP002229750 & ALCOHOLISM CLINICAL AND EXPERIMENTAL RESEARCH, vol. 7, no. 2, 1983, pages 135-139, ISSN: 0145-6008
JUNIEWICZ P E ET AL: "EFFECT OF COMBINATION TREATMENT WITH ZANOTERONE (WIN 49596), A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST, AND FINASTERIDE (MK-906), A STEROIDAL 5ALPHA-REDUCTASE INHIBITOR, ON THE PROSTATE AND TESTES OF BEAGLE DOGS" ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 133, no. 2, 1993, pages 904-913, XP008012035 ISSN: 0013-7227
MAKLAD ET AL.: "Androgenic adnd anabolic activities of some newly synthetized epiandrosterone and progesterone derivatives" SCIENTIA PHARMACEUTICA, vol. 68, no. 2, 30 June 2000 (2000-06-30), pages 141-157, XP008013051

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).